|
|
|
|
CORRECT: FDA: Low Response Rate Seen With Proposed Drug Omapro
('FDA Low Response Rate Seen With Proposed Drug Omapro >CXS.AU', published at 10:12 a.m.EST, mistated the name of a type of leukemia. A correct version follows.) Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The Food and Drug Administration said...
|
|
|
CORRECT: FDA: Low Response Rate Seen With Proposed Drug Omapro
("FDA Low Response Rate Seen With Proposed Drug Omapro >CXS.AU", published at 10:12 a.m.EST, mistated the name of a type of leukemia. A correct version follows.) WASHINGTON -(Dow Jones)- The Food and Drug Administration said Monday that the response...
|
|
|
UPDATE: FDA: Low Response Rate Seen With Proposed Drug Omapro
(Updates with FDA panel meeting postponement) WASHINGTON -(Dow Jones)- The Food and Drug Administration said Monday that the response rate seen in a study of a proposed ChemGenex Pharmaceuticals Ltd.(CXSPY, CXS.AU) drug to treat certain type of patients with...
|
|
|
CORRECT: FDA: Low Response Rate Seen With Proposed Drug Omapro
("FDA Low Response Rate Seen With Proposed Drug Omapro >CXS.AU", published at 10:12 a.m.EST, mistated the name of a type of leukemia. A correct version follows.) WASHINGTON -(Dow Jones)- The Food and Drug Administration said Monday that the response...
|
|
|
UPDATE: FDA: Low Response Rate Seen With Proposed Drug Omapro
(Updates with FDA panel meeting postponement) WASHINGTON -(Dow Jones)- The Food and Drug Administration said Monday that the response rate seen in a study of a proposed ChemGenex Pharmaceuticals Ltd.(CXSPY, CXS.AU) drug to treat certain type of patients with...
|
|
|
CORRECT: FDA: Low Response Rate Seen With Proposed Drug Omapro
("FDA Low Response Rate Seen With Proposed Drug Omapro CXS.AU", published at 9:57 a.m.EST, mistated the name of a type of leukemia. A correct version follows.) By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The Food and Drug...
|
|
|
CORRECT: FDA: Low Response Rate Seen With Proposed Drug Omapro
('FDA Low Response Rate Seen With Proposed Drug Omapro >CXS.AU', published at 10:12 a.m.EST, mistated the name of a type of leukemia. A correct version follows.) Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The Food and Drug Administration said...
|
|
|
UPDATE: FDA: Low Response Rate Seen With Proposed Drug Omapro
(Updates with FDA panel meeting postponement) Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The Food and Drug Administration said Monday that the response rate seen in a study of a proposed ChemGenex Pharmaceuticals Ltd.( CXSPY, CXS.AU) drug to treat...
|
|
|
UPDATE: FDA: Low Response Rate Seen With Proposed Drug Omapro
(Updates with FDA panel meeting postponement) By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The Food and Drug Administration said Monday that the response rate seen in a study of a proposed ChemGenex Pharmaceuticals Ltd.(CXSPY,...
|
|
|
UPDATE: FDA: Low Response Rate Seen With Proposed Drug Omapro
(Updates with FDA panel meeting postponement) Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The Food and Drug Administration said Monday that the response rate seen in a study of a proposed ChemGenex Pharmaceuticals Ltd.( CXSPY, CXS.AU) drug to treat...
|
|
|
NICE says pharma should help pay for leukemia drugs
Government regulators in Britain are asking Novartis and Bristol-Myers Squibb to help pay for their leukemia drugs.In a statement today, the National Institute for Health and Clinical Excellence (NICE) took issue with price points on BMS's Sprycel and...
|
|
|
Reportlinker Adds Kinase Therapeutics: Pipeline Assessment and Commercial Prospects - Overview
Companies mentioned in this article: ReportLinker NEW YORK, Feb.9 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: http://www.reportlinker.com/p0176024/Kinase-Therapeutics-Pipeline-Assessment-and...
|
|
|
Reportlinker Adds Kinase Therapeutics: Pipeline Assessment and Commercial Prospects - Overview
Reportlinker Adds PR Newswire NEW YORK, Feb.9 NEW YORK, Feb. 9 /PRNewswire/ -- Reportlinker.com announces that a new is available in its catalogue: http://www.reportlinker.com/p0176024/Kinase-Therapeutics-Pipeline-Assessment-and-Commercial-Prospects--...
|
|
|
Reportlinker Adds Kinase Therapeutics: Pipeline Assessment and Commercial Prospects - Overview
Reportlinker Adds PR Newswire NEW YORK, Feb.9 NEW YORK, Feb. 9 /PRNewswire/ -- Reportlinker.com announces that a new is available in its catalogue: http://www.reportlinker.com/p0176024/Kinase-Therapeutics-Pipeline-Assessment-and-Commercial-Prospects--...
|
|
|
Reportlinker Adds Kinase Therapeutics: Pipeline Assessment and Commercial Prospects - Overview
NEW YORK, Feb.9 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Kinase Therapeutics: Pipeline Assessment and Commercial Prospects - Overview http://www.reportlinker.com/p0176024/Kinase-Therapeutics...
|
|
|
Reportlinker Adds Kinase Therapeutics: Pipeline Assessment and Commercial Prospects - Overview
Reportlinker Adds PR Newswire NEW YORK, Feb.9 NEW YORK, Feb. 9 /PRNewswire/ -- Reportlinker.com announces that a new is available in its catalogue: http://www.reportlinker.com/p0176024/Kinase-Therapeutics-Pipeline-Assessment-and-Commercial-Prospects--...
|
|
|
Reportlinker Adds Kinase Therapeutics: Pipeline Assessment and Commercial Prospects - Overview
Overview PR Newswire NEW YORK, Feb.9 NEW YORK, Feb. 9 /PRNewswire/ -- Reportlinker.com announces that a new is available in its catalogue: http://www.reportlinker.com/p0176024/Kinase-Therapeutics-Pipeline-Assessment-and-Commercial-Prospects---Overview.html...
|
|
|
Reportlinker Adds Kinase Therapeutics: Pipeline Assessment and Commercial Prospects - Overview
Reportlinker Adds PR Newswire NEW YORK, Feb.9 NEW YORK, Feb. 9 /PRNewswire/ -- Reportlinker.com announces that a new is available in its catalogue: http://www.reportlinker.com/p0176024/Kinase-Therapeutics-Pipeline-Assessment-and-Commercial-Prospects--...
|
|
|
ChemGenex shares dive on FDA's leukemia drug critique
With the FDA's oncology experts preparing to gather to consider the fate of ChemGenex Pharmaceuticals' experimental leukemia drug Omapro, FDA staffers are questioning the clinical significance of the therapy.And their skeptical stance triggered a steep dive...
|
|
|
Reportlinker Adds Kinase Therapeutics: Pipeline Assessment and Commercial Prospects - Overview
GA_googleFillSlot("Press336"); GA_googleFillSlot("Press160"); NEW YORK, Feb.9 /PRNewswire/ -- Reportlinker.com announces that a new is available in its catalogue: http://www.reportlinker.com/p0176024/Kinase-Therapeutics-Pipeline-Assessment-and-Commercial...
|
|
|
Reportlinker Adds Kinase Therapeutics: Pipeline Assessment and Commercial Prospects - Overview
See more news releases in: Computer Electronics, Multimedia & Internet, Publishing & Information Services, Biotechnology, Medical Pharmaceuticals, Pharmaceuticals, Surveys, Polls and Research NEW YORK, Feb.9 /PRNewswire/ -- Reportlinker.com announces...
|
|
|
UK Body Says Novartis, Bristol Cancer Drugs Too Expensive
LONDON -(Dow Jones)- The U.K.'shealth-cost regulator said Tuesday it was unable to recommend two expensive cancer drugs from Novartis AG (NVS) and one from U.S.-based Bristol-Myers Squibb Co.(BMY) for use within the state-run National Health Service in...
|
|
|
UK Body Says Novartis, Bristol Cancer Drugs Too Expensive (DJ)
UK Body Says Novartis, Bristol Cancer Drugs Too Expensive LONDON -(Dow Jones)- The U.K.'s health-cost regulator said Tuesday it was unable to recommend two expensive cancer drugs from Novartis AG (NVS) and one from U.S.-based Bristol-Myers Squibb Co.(BMY)...
|
|
|
Limited Benefit Seen in CML Drug, FDA Says
WASHINGTON -- Chronic myeloid leukemia (CML) patients who are resistant to imatinib (Gleevec) had a low response rate to treatment with omacetaxine (Omapro), according to Food and Drug Administration (FDA) reviewers.The FDA released its assessment of...
|
|
|
UK Body Says Novartis, Bristol Cancer Drugs Too Expensive
LONDON -(Dow Jones)- The U.K.'s health-cost regulator said Tuesday it was unable to recommend two expensive cancer drugs from Novartis AG (NVS) and one from U.S.-based Bristol-Myers Squibb Co.(BMY) for use within the state-run National Health Service in...
|
